AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38178168 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and esketamine in combination (P + K)
Number of subjects: 100
Study 38178168 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and lidocaine in combination (P + L)
Number of subjects: 100
Study 38178168 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine with propofol
Number of subjects: 100
Study 38178180 — intervention group
Group type: EXPERIMENTAL
Intervention: One-point fixation at zygomaticomaxillary buttress
Number of subjects: 0
Study 38178223 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Bifidobacterium lactis BI040, B. longum BL020, Lactobacillus rhamnosus LR110, L. casei LC130, L. acidophilus LA120, 5 billion CFU total)
Number of subjects: 73
Study 38178223 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 73
Study 38178223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 38178229 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D
Number of subjects: 307
Study 38178233 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS-methylphenidate (OROS-MPH)
Number of subjects: 150
Study 38178233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 38178267 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) provided by physical therapists for 12 weeks
Number of subjects: 48
Study 38178267 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron for 12 weeks
Number of subjects: 48
Study 38178267 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride for 12 weeks
Number of subjects: 48
Study 38178267 — intervention group
Group type: COMPARATOR
Intervention: All interventions (PFMT, mirabegron, trospium)
Number of subjects: 48
Study 38178318 — intervention group
Group type: COMPARATOR
Intervention: NST device volume turned off (Control)
Number of subjects: 44
Study 38178318 — intervention group
Group type: EXPERIMENTAL
Intervention: NST device volume 1-35 dB(A)
Number of subjects: 44
Study 38178318 — intervention group
Group type: EXPERIMENTAL
Intervention: NST device volume 36-60 dB(A)
Number of subjects: 44
Study 38178318 — intervention group
Group type: EXPERIMENTAL
Intervention: NST device volume 61 dB(A) and above
Number of subjects: 44
Study 38178318 — intervention group
Group type: EXPERIMENTAL
Intervention: All intervention groups (1-35 dB(A), 36-60 dB(A), 61 dB(A) and above)
Number of subjects: 44
Study 38178322 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) application via virtual glasses during pelvic examination
Number of subjects: 128
Study 38178322 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 128
Study 38178557 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 24
Study 38178557 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1ra
Number of subjects: 24
Study 38178557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 38178863 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38178887 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) for acute basilar artery occlusion (BAO)
Number of subjects: 185
Study 38179107 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 32
Study 38179107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 38179189 — intervention group
Group type: EXPERIMENTAL
Intervention: 3T MR scanner
Number of subjects: 26
Study 38179309 — intervention group
Group type: EXPERIMENTAL
Intervention: Unintentional changes in body mass index (BMI)
Number of subjects: 10251
Study 38179309 — intervention group
Group type: EXPERIMENTAL
Intervention: Unintentional changes in waist circumference (WC)
Number of subjects: 10251
Study 38179309 — intervention group
Group type: EXPERIMENTAL
Intervention: Third tertiles of BMI change
Number of subjects: 10251
Study 38179309 — intervention group
Group type: EXPERIMENTAL
Intervention: Third tertiles of WC change
Number of subjects: 10251
Study 38179309 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable BMI and WC
Number of subjects: 10251
Study 38179809 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg
Number of subjects: 525
Study 38179936 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate low-dose radiotherapy, dosage and duration not available
Number of subjects: 0
Study 38180092 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arrest crS o2 monitoring during cardiopulmonary resuscitation
Number of subjects: 123
Study 38180092 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher crS o2 during CPR
Number of subjects: 123
Study 38180092 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher crS o2 during CPR in infants (< 1 yr)
Number of subjects: 123
Study 38180230 — intervention group
Group type: EXPERIMENTAL
Intervention: Children admitted for COVID-19
Number of subjects: 36
Study 38180230 — intervention group
Group type: EXPERIMENTAL
Intervention: Children hospitalized for COVID-19
Number of subjects: 36
Study 38180268 — intervention group
Group type: COMPARATOR
Intervention: Disulfiram
Number of subjects: 1191
Study 38180338 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric breast MRI (including DWI and DCE MRI)
Number of subjects: 191
Study 38180348 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ride-on car (ROC) with standing for 70 min
Number of subjects: 19
Study 38180348 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ride-on car (ROC) with various postural combinations
Number of subjects: 19
Study 38180893 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV IgG titer
Number of subjects: 717
Study 38180983 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (CTX) 1 gr/day for up to 7 days
Number of subjects: 30
Study 38180983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 38181004 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Management Plus and 'Thinking Healthy' interventions combined with specific parts of the Strong Minds-Strong Communities intervention
Number of subjects: 265
Study 38181004 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 265
Study 38181048 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV-AS03
Number of subjects: 20
Study 38181048 — intervention group
Group type: COMPARATOR
Intervention: IIV
Number of subjects: 20
Study 38181311 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor plus aspirin
Number of subjects: 6412
Study 38181311 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel plus aspirin
Number of subjects: 6412
Study 38181312 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI/Cet)
Number of subjects: 606
Study 38181312 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab alone (Control)
Number of subjects: 606
Study 38181433 — intervention group
Group type: EXPERIMENTAL
Intervention: BMMNC treatment
Number of subjects: 47
Study 38181547 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital involvement in COVID-19-related care
Number of subjects: 100
Study 38181724 — intervention group
Group type: EXPERIMENTAL
Intervention: Levcromakalim (0.05 mg/ml infusion)
Number of subjects: 16
Study 38181724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 38181782 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous high-dose methotrexate (MTX) 1.5 g/m2 after 6 cycles of R-CHOP regimen; IT liposomal cytarabine administered on day 0 of cycles 2 to 5 of R-CHOP; contralateral testis radiotherapy (25-30 Gy) recommended.
Number of subjects: 54
Study 38181782 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, every 21 days).
Number of subjects: 54
Study 38181784 — intervention group
Group type: EXPERIMENTAL
Intervention: SCD pre-HSCT
Number of subjects: 20
Study 38181784 — intervention group
Group type: COMPARATOR
Intervention: SCD post-HSCT
Number of subjects: 20
Study 38181784 — intervention group
Group type: COMPARATOR
Intervention: HbAS
Number of subjects: 20
Study 38181784 — intervention group
Group type: COMPARATOR
Intervention: HbAA
Number of subjects: 20
Study 38181791 — intervention group
Group type: EXPERIMENTAL
Intervention: Olgotrelvir (STI-1558)
Number of subjects: 0
Study 38181791 — intervention group
Group type: EXPERIMENTAL
Intervention: AC1115 (active form of Olgotrelvir)
Number of subjects: 0
Study 38181795 — intervention group
Group type: EXPERIMENTAL
Intervention: serplulimab 4.5 mg/kg plus nab-paclitaxel and carboplatin
Number of subjects: 537
Study 38181795 — intervention group
Group type: COMPARATOR
Intervention: placebo plus nab-paclitaxel and carboplatin
Number of subjects: 537
Study 38181820 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach-oriented coping
Number of subjects: 360
Study 38181820 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidant coping
Number of subjects: 360
Study 38181882 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (sleeve gastrectomy and Roux-en-Y gastric bypass)
Number of subjects: 28
Study 38181882 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 28
Study 38181882 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (RYGB)
Number of subjects: 28
Study 38182130 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38182406 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep immunophenotyping using 13 flow cytometry panels
Number of subjects: 443
Study 38182406 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised clustering
Number of subjects: 443
Study 38182406 — intervention group
Group type: EXPERIMENTAL
Intervention: Principal component analysis
Number of subjects: 443
Study 38182406 — intervention group
Group type: EXPERIMENTAL
Intervention: First axis driven by the ratio of LAG3+ to ICOS+ in regulatory T lymphocytes (Tregs)
Number of subjects: 443
Study 38182406 — intervention group
Group type: EXPERIMENTAL
Intervention: Second axis driven by activated Tregs and type 3 innate lymphoid cells (ILC3s)
Number of subjects: 443
Study 38182456 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IVT) with tPA
Number of subjects: 221
Study 38182456 — intervention group
Group type: COMPARATOR
Intervention: No intravenous thrombolysis (no IVT)
Number of subjects: 221
Study 38182456 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IVT)
Number of subjects: 221
Study 38182456 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT)
Number of subjects: 221
Study 38182483 — intervention group
Group type: EXPERIMENTAL
Intervention: Online breastfeeding education
Number of subjects: 50
Study 38182483 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 50
Study 38182687 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus plus exemestane
Number of subjects: 150
Study 38182784 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium-Ibogaine therapy
Number of subjects: 30
Study 38182785 — intervention group
Group type: EXPERIMENTAL
Intervention: Ripretinib 150 mg once daily
Number of subjects: 362
Study 38182785 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib 50 mg
Number of subjects: 362
Study 38182785 — intervention group
Group type: EXPERIMENTAL
Intervention: Ripretinib 150 mg
Number of subjects: 362
Study 38182792 — intervention group
Group type: EXPERIMENTAL
Intervention: SAGA intervention (Social Games for Autistic Adolescents)
Number of subjects: 0
Study 38182792 — intervention group
Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 0
Study 38182919 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergames Program (EP)
Number of subjects: 20
Study 38182919 — intervention group
Group type: COMPARATOR
Intervention: Conventional Exercise Program (CP)
Number of subjects: 20
Study 38182919 — intervention group
Group type: COMPARATOR
Intervention: Comparison of EP vs CP
Number of subjects: 20
Study 38182920 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced characterization of serum glycoprotein and lipoprotein profile measured by proton nuclear magnetic resonance spectroscopy
Number of subjects: 323
Study 38183045 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular joint-protective exercise therapy program
Number of subjects: 48
Study 38183045 — intervention group
Group type: COMPARATOR
Intervention: Training program with ROM exercises
Number of subjects: 48
Study 38183047 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Cardiac Surgery (ERACS) bundle strategy including preoperative, intraoperative, and postoperative approaches.
Number of subjects: 3030
Study 38183047 — intervention group
Group type: COMPARATOR
Intervention: Usual care during the control phase.
Number of subjects: 3030
Study 38183062 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-enriched medium cross-linked polyethylene (MXE)
Number of subjects: 0
Study 38183062 — intervention group
Group type: COMPARATOR
Intervention: Standard polyethylene gliding surface
Number of subjects: 0
Study 38183067 — intervention group
Group type: EXPERIMENTAL
Intervention: Health services used in Denmark (consultations at outpatient clinics, visits to general practitioners, visits to fitness centres)
Number of subjects: 3417
Study 38183067 — intervention group
Group type: COMPARATOR
Intervention: Health services used in Norway (visits to general practitioners, rehospitalisation, no follow-up)
Number of subjects: 3417
Study 38183067 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived need for follow-up and information
Number of subjects: 3417
Study 38183081 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% propolis mouthwash
Number of subjects: 144
Study 38183081 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine mouthwash
Number of subjects: 144
Study 38183089 — intervention group
Group type: EXPERIMENTAL
Intervention: Breaking the Cycle intervention program
Number of subjects: 100
Study 38183089 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxxine Wright intervention program
Number of subjects: 100
Study 38183121 — intervention group
Group type: EXPERIMENTAL
Intervention: Dog present but not integrated in the therapeutic narrative
Number of subjects: 150
Study 38183121 — intervention group
Group type: EXPERIMENTAL
Intervention: Dog actively integrated in the therapeutic narrative
Number of subjects: 150
Study 38183121 — intervention group
Group type: COMPARATOR
Intervention: No dog present
Number of subjects: 150
Study 38183121 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapists' evaluations
Number of subjects: 150
Study 38183121 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment adherence
Number of subjects: 150
Study 38183121 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment satisfaction
Number of subjects: 150
Study 38183137 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 240
Study 38183137 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir
Number of subjects: 240
Study 38183154 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth delivery of nonpharmacologic care from physical therapists
Number of subjects: 0
Study 38183154 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies focusing on training, education, clinician support, and tailoring physical therapy interventions for telehealth delivery and cultural competency
Number of subjects: 0
Study 38183273 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 75
Study 38183273 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab with statin and/or ezetimibe
Number of subjects: 75
Study 38183273 — intervention group
Group type: COMPARATOR
Intervention: Evolocumab alone
Number of subjects: 75
Study 38183497 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg intravenous preoperatively)
Number of subjects: 75
Study 38183497 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg in initial irrigation fluid)
Number of subjects: 75
Study 38183497 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tranexamic acid)
Number of subjects: 75
Study 38183497 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (both groups)
Number of subjects: 75
Study 38183525 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) in a treat-and-extend (T&E) regimen (n=168)
Number of subjects: 332
Study 38183525 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal aflibercept (IVT-AFL) fixed dosing regimen (n=168)
Number of subjects: 332
Study 38183526 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC 100 mg (44 mg rac-tramadol hydrochloride/56 mg celecoxib; n=164)
Number of subjects: 726
Study 38183526 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC 150 mg (66 mg rac-tramadol hydrochloride/84 mg celecoxib; n=160)
Number of subjects: 726
Study 38183526 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC 200 mg (88 mg rac-tramadol hydrochloride/112 mg celecoxib; n=160)
Number of subjects: 726
Study 38183526 — intervention group
Group type: COMPARATOR
Intervention: Tramadol 100 mg four times daily (n=159)
Number of subjects: 726
Study 38183526 — intervention group
Group type: COMPARATOR
Intervention: Placebo four times daily (n=83)
Number of subjects: 726
Study 38183804 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy for insomnia (CBT-I)
Number of subjects: 108
Study 38183804 — intervention group
Group type: COMPARATOR
Intervention: Sham Quasi-Desensitization Therapy for Insomnia (DTI)
Number of subjects: 108
Study 38184008 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg twice daily for 7 days
Number of subjects: 278
Study 38184008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 38184303 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV-targeting T cell receptor-engineered T (CMV-TCR-T) cell therapy, administered in 1 to 3 doses.
Number of subjects: 6
Study 38184304 — intervention group
Group type: EXPERIMENTAL
Intervention: VB-111 (ofranergene obadenovec) and nivolumab
Number of subjects: 14
Study 38184414 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab
Number of subjects: 42
Study 38184414 — intervention group
Group type: COMPARATOR
Intervention: Control isotype
Number of subjects: 42
Study 38184414 — intervention group
Group type: EXPERIMENTAL
Intervention: Preclinical model with anti-PD-1 antibody
Number of subjects: 42
Study 38184428 — intervention group
Group type: EXPERIMENTAL
Intervention: avalglucosidase alfa
Number of subjects: 99
Study 38184428 — intervention group
Group type: COMPARATOR
Intervention: alglucosidase alfa
Number of subjects: 99
Study 38184475 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention consisting of short video lectures on obesity, vignettes simulating interactions with PwO, and open discourse with a PwO.
Number of subjects: 162
Study 38184475 — intervention group
Group type: COMPARATOR
Intervention: Control group received a short-written document on obesity.
Number of subjects: 162
Study 38184489 — intervention group
Group type: EXPERIMENTAL
Intervention: HSK7653
Number of subjects: 42
Study 38184489 — intervention group
Group type: COMPARATOR
Intervention: Control (normal renal function)
Number of subjects: 42
Study 38184491 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Home Exercise Group (SHEG)
Number of subjects: 45
Study 38184491 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Exercise Group (HEG)
Number of subjects: 45
Study 38184491 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 45
Study 38184507 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan, initiated as combination therapy in 74.8% of patients, median exposure 11.9 months (Q1, Q3: 3.1, 26.0)
Number of subjects: 206
Study 38184507 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan
Number of subjects: 206
Study 38184559 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief physical activity and diet intervention (PACE)
Number of subjects: 25
Study 38184559 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare provider training and support
Number of subjects: 25
Study 38184559 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized approach to intervention
Number of subjects: 25
Study 38184559 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual factors (e.g., COVID-19 pandemic)
Number of subjects: 25
Study 38184582 — intervention group
Group type: COMPARATOR
Intervention: SGLT-2i
Number of subjects: 443
Study 38184582 — intervention group
Group type: COMPARATOR
Intervention: GLP-1RA
Number of subjects: 443
Study 38184582 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT-2i/GLP-1RA combination therapy
Number of subjects: 443
Study 38184633 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of smoking cessation interventions at outpatient OAT clinics, including weekly follow-up, a short behavioural intervention, and provision of nicotine replacement products.
Number of subjects: 0
Study 38184633 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group).
Number of subjects: 0
Study 38184642 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person cognitive behavioral therapy (CBT)
Number of subjects: 3
Study 38184642 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3
Study 38184737 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney BEAM intervention
Number of subjects: 42
Study 38184737 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 42
Study 38184920 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvaliase treatment
Number of subjects: 250
Study 38184927 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) using the Epic Roller Coasters application
Number of subjects: 69
Study 38184927 — intervention group
Group type: COMPARATOR
Intervention: Control group (no distraction method)
Number of subjects: 69
Study 38184927 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 69
Study 38185111 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care and outpatient comprehensive geriatric care (CGC) clinic
Number of subjects: 53
Study 38185111 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 53